Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer

Annals of Thoracic Surgery

Volumn 78, Issue 3, 2004, Pages 1037-1041

  Voelter, Verena ^a   Schuhmacher, Christoph ^b   Busch, Raymonde ^b   Peschel, Christian ^a   Rüdiger Siewert, Jörg ^b   Lordick, Florian ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

7

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; HEMOGLOBIN; OXALIPLATIN; PACLITAXEL;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; BLOOD TRANSFUSION; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; ESOPHAGOGASTRIC CANCER; ESOPHAGUS CANCER; FEMALE; HUMAN; INCIDENCE; MALE; POSTOPERATIVE COMPLICATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; STATISTICAL SIGNIFICANCE; STOMACH CANCER;

EID: 4444292758     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2004.01.049     Document Type: Article

References (41)

1. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727-33
2. Chau I, Cunningham D. Perioperative chemotherapy for cancer of the esophagus and the esophagogastric junction. ASCO Educational Book 2003:429-40
3. Allum W, Cunningham D, Weeden. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: A randomized trial (the MAGIC trial, ISRCTN 93793971). Proc. ASCO 2003, No. 998
4. Kelsen D., Pajak T., Ginsberg R. Treatment of esophageal cancer. N Engl J Med. 340:1999;1685-1687
5. Groopman J.E., Itri L.M. Chemotherapy-induced anemia in adults incidence and treatment. J Natl Cancer Inst. 91:1999;1616-1634
6. Busch O., Hop W., Hoynck van Papendrecht M., Marquet R.L., Jeekel J. Blood transfusions and prognosis in colorectal cancer. N Engl J Med. 328:1993;1372-1376
7. Burrows L., Tartter P. Effect of blood transfusion on colonic malignancy recurrence rate. Lancet. 18:1982;662
8. Fong Y., Karpeh M., Mayer K., Brennan M.F. Association of perioperative transfusions with poor outcome after resection of gastric adenocarcinoma. Am J Surg. 167:1994;256-260
9. Jones K.R., Weissler M.C. Blood transfusion and other risk factors for recurrence of cancer of the head and neck. Arch Otolaryngol Head Neck Surg. 116:1990;304-309
10. Rosenberg S.A., Seipp C.A., White D.E., Wesley R. Perioperative blood transfusions are associated with increased rates of recurrence and decreased survival in patients with high-grade soft-tissue sarcomas of the extremities. J Clin Oncol. 3:1985;698-709
11. Yamamoto J., Kosuge T., Takayama T., et al. Perioperative blood transfusion promotes recurrence of hepatocellular carcinoma after hepatectomy. Surgery. 115:1994;303-309
12. Dresner S.M., Lamb P.J., Shenfine J., Hayes N., Griffin S.M. Prognostic significance or peri-operative blood transfusion following radical resection for oesophageal carcinoma. Eur J Surg Oncol. 26:2000;492-497
13. Langley S.M., Alexiou C., Bailey D.H., Weeden D.F. The influence of perioperative blood transfusion on survival after esophageal resection for carcinoma. Ann Thorac Surg. 73:2002;1704-1709
14. Siewert J.R., Stein H.J. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 85:1998;1457-1459
15. Cancer therapy evaluation program. Common toxicity criteria, version 2.0, 1998. Available at: http://ctep.cancer.gov/reporting/ctc.html
16. Weber W.A., Ott K., Becker K., et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 19:2001;3058-3065
17. Ott K., Fink U., Becker K., et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging results of a prospective trial. J Clin Oncol. 21:2003;4604-4610
18. DelMastro L., Gennari A., Donati S. Chemotherapy of non-small-cell lung cancer role of erythropoietin in the management of anemia. Ann Oncol. 10:(Suppl 5):1999;91-94
19. Okamoto H., Saijo N., Shinkai T., et al. Chemotherapy-induced anemia in patients with primary lung cancer. Ann Oncol. 3:1992;819-824
20. Lang P., Buisson C., Fruchaud G., et al. Long-term results of posttransplantation blood transfusion on kidney allograft survival. Transplant Proc. 33:2001;1202-1203
21. Tachibana M., Tabara H., Kotoh T., et al. Prognostic significance of perioperative blood transfusion in resectable thoracic esophageal cancer. Am J Gastroenterol. 94:1999;757-765
22. Edna T.H., Bjerkeset T. Perioperative blood transfusions reduce long-term survival following surgery for colorectal cancer. Dis Colon Rectum. 41:1998;451-459
23. Moriguchi S., Machara Y., Akazawa K., Sugimachi K., Nose Y. Lack of relationship between perioperative blood transfusion and survival time after curative resection for gastric cancer. Cancer. 66:1990;2331-2335
24. Pastorino U., Valente M., Cataldo I., Lequaglie C., Ravasi G. Perioperative blood transfusion and prognosis of resected stage Ia lung cancer. Eur J Cancer Clin Oncol. 22:1986;1375-1378
25. Chung M., Steinmetz O.K., Gordon P.H. Perioperative blood transfusion and outcome after resection for colorectal carcinoma. Br J Surg. 80:1993;427-431
26. Craig S.R., Adam D.J., Yap P.L., et al. Effect of blood transfusion on survival after esophagogastrectomy for carcinoma. Ann Thorac Surg. 66:1998;356-361
27. Lutterbach J., Guttenbacher R. Anemia is associated with decreased local control of surgically treated squamous cell carcinomas of the glottic pharynx. Int J Radiat Oncol Biol Phys. 48:2000;1345-1350
28. Frommhold H., Guttenberger R., Henke M. The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience. Strahlenther Onkol. 174:(Suppl 4):1998;31-34
29. Glaser C.M., Millesi W., Kornek G.V., et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity. Int J Radiat Oncol Biol Phys. 50:2001;705-715
30. Glaspy J.A. The potential for anemia treatment to improve survival in cancer patients. Oncology Huntingt. 16:(9 Suppl 10):2002;35-40
31. Robnett T.J., Machtay M., Hahn S.M., Shrager J.B., Friedberg J.S., Kais L.R. Pathological response to preoperative chemoradiation worsens with anemia in non-small cell lung cancer patients. Cancer J. 8:2002;263-267
32. Becker A, Stadler P, Lavey RS, Hansgen et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2000;46:459-66
33. Thews O., Kelleher D.K., Vaupel P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res. 61:2001;1358-1361
34. Crawford J. Recombinant human erythropoietin in cancer-related anemia. Review of clinical experience. Oncology Huntingt. 16:(9 Suppl 10):2002;41-53
35. Bamias A., Aravantinos G., Kalofonos C., et al. Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erthropoietin (rHuEpo) a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology. 64:2003;102-110
36. Littlewood T.J., Bajetta E., Nortier J.W.R., Vercammen E., Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy results of a randomized, double-blind placebo-controlled trial. J Clin Oncol. 19:2001;2865-2874
37. Vansteenkiste J., Pirker R., Massuti B., et al. Double-blind placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 94:2002;1211-1220
38. Glaspy J., Bukowski R., Steinberg D., Taylor C., Tchekmedyian S., Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol. 15:1997;1218-1234
39. Demetri G.D., Kris M., Wade J., Degos L., Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type results from a prospective community oncology study. J Clin Oncol. 16:1998;3412-3425
40. Tchekmedyian N.S. Anemia in cancer patients significance, epidemiology and current therapy. Oncology Huntingt. 16:(9 Suppl 10):2002;17-24
41. Dunne J.R., Malone D., Tracy J.K., Gannon C., Napolitano L.M. Perioperative anemia an independent risk factor for infection, mortality, and resource utilization in surgery. J Surg Res. 102:2002;237-244